Rapid Detection and Monitoring of Biomarkers for Traumatic Brain Injury

标题：创伤性脑损伤生物标志物的快速检测和监测 项目概要/摘要： 美国每人有超过370，000人因脑外伤（TBI）住院 年在美国，与治疗、住院和康复相关的费用 TBI每年估计为483亿美元。一个快速、简单、准确和有效的 需要进行脑损伤测试，以确定头部创伤并监测脑损伤的进展。 条件一旦发生与TBI相关的主要影响，快速反应至关重要 以限制由于颅压增加而造成的二次损伤的影响， 离子运输过程中的异常变化。脑损伤后神经蛋白质组学变化 患者是指示TBI的复杂分子事件的基础。高- 对这些蛋白质组变化的快速和高即时性评估应该允许 TBI的特异性和敏感性诊断以及病情的持续评估。 辐射监测设备提出开发一种紧凑的，一次性的微流体 该传感器将从血液样本中快速检测一组多个TBI生物标志物。 为了实现这一点，我们将集成硅基CMOS（互补金属氧化物 半导体）光子计数光学（GPD）检测器直接进入微流体芯片 其将使用荧光以非常高的灵敏度检测靶蛋白组分 标记单克隆抗体。这种高灵敏度是通过放置 光子检测器非常接近微流体内的荧光信号源 频道 在第一阶段，我们将修改现有的微流体传感器，以开发一个测试平台， 演示光子计数探测器的集成，并进行临床测量 模型样品中TBI生物标志物的显著浓度。在第二阶段，我们将 优化微流控系统的设计，开发在“掌上电脑”上运行的软件， 用于数据分析和用户界面的计算机，并测量脑组织中的TBI生物标志物 脊髓液由此产生的装置将是一个通用的检测技术平台 在一个单位中的多种蛋白质。

Title: Rapid detection and monitoring of biomarkers for traumatic brain injury Project Summary/Abstract: Over 370,000 people in the US are hospitalized for traumatic brain injury (TBI) each year. In the US, the cost associated with the treatment, hospitalization and rehabilitation of TBI are estimated to be $48.3 billion annually. A fast, easy, accurate and effective test for brain injury is required to identify head trauma and monitor the progression of the condition. Once the primary impact associated with TBI occurs, rapid response is critical to limit the impact of the secondary damage due to increased cranial pressure and abnormal changes in ion transport processes. Neuroproteomic changes in injured patients underlie the complex molecular events that are indicative of TBI. The high- speed and high-immediacy assessment of these proteomic changes should permit the specific and sensitive diagnosis of TBI and continued evaluation of the condition. Radiation Monitoring Devices proposes to develop a compact, disposable microfluidic sensor that will rapidly detect a panel of multiple TBI biomarkers from a blood sample. To accomplish this, we will integrate silicon-based CMOS (complementary metal oxide semiconductor) photon counting optical (GPD) detectors directly into a microfluidic chip which will detect target protein components with very high sensitivity using fluorescently label monoclonal antibodies. This high sensitivity is achieved by the placement of the photon detectors very close to the source of the fluorescent signal within the microfluidic channel. In Phase I, we will modify an existing microfluidic sensor to develop a test platform to demonstrate the integration of the photon-counting detector, and measure clinically significant concentrations of TBI biomarkers in model samples. In Phase II, we will optimize the design of the microfluidic system, develop software to run on a "palmtop" computer for data analysis and user interface, and measure TBI biomarkers in cerebral spinal fluid. The resulting device will be a general technology platform for the detection of multiple proteins in a single unit.